An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Guangzhou FineImmune Biotechnology Co., LTD. in Sarcoma, Lung Cancers, Melanoma. SEO and diligence focus: Super1 TCR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.